Your SlideShare is downloading. ×
Vesrisante Technology
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Vesrisante Technology


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. 2Forward Looking StatementsThis presentation contains certain forward-looking statements. Thesestatements relate to future events or future performance and reflectmanagement’s expectations and assumptions regarding growth,results of operations, performance and business prospects andopportunities. Such forward-looking statements reflectmanagement’s current beliefs and are based on informationcurrently available to management. A number of factors could cause actual events to differ materially. Inevaluating these statements, prospective purchasers shouldspecifically consider various risks as more fully outlined in theprospectus, a copy of which can be obtained online 2
  • 2. 3“There’s an epidemic of skin cancer” - Howard Rogers, Dermatologist, Lead on Medicare research Skin cancer strikes 1 in 5 in the U.S.1 It is the most common form of cancer 40-50% of Americans who live to 65 expected to get skin cancer 2 Melanoma kills one person every hour in the US 3 Melanoma is the #1 cancer killer of women 25-30 4 Incidence of melanoma rising faster than any other cancer 5 Melanoma is Deadly Accounts for 75% of skin cancer deaths6 3
  • 3. 4Early detection vital to saving lives 100 95% Melanoma Five Year Survival Rate by Tumor Stage 6 80 60 40 20 15% 0 Stage I Stage II Stage III Stage IV
  • 4. 5Early detection would save billions of dollars 2 million Americans get skin cancer each year 7 Cost of Treating Melanoma by Tumor Stage (per patient) 9 Treating melanoma alone costs $1.5 billion 110.1 ($ US thousands) annually in the U.S. 8 105.5 Advanced stage melanoma 22 times more costly to treat than early stage 35.4 38.3 22.5 24.3 11.0 13.7 5.0 Early Stage Late Stage
  • 5. 6Current skin cancer detection methods limited Primary diagnosis done by GPs with varying Clinical Diagnosis Histological Diagnosis levels of experience Full body examinations seldom conducted 33.8% sensitivity for melanoma for GPs 10 › Squamous Cell Carcinoma – 41.1% › Basal Cell Carcinoma – 63.9% Punch Biopsy Biopsies invasive and costly › Permanent scarring ~80% of biopsies test negative 11
  • 6. 7Breakthrough early stage cancer detection system Initial Focus: Early detection of skin cancer Detects melanoma with 97% accuracy vs. 33.8% for primary clinical diagnosis All forms of Skin Cancer Developed by BC Cancer Agency and UBC Patented technology Exclusively licensed to Verisante Technology, Inc. Gastrointestinal, Lung, and Cervical Cancers
  • 7. 8Highly automated detection process Skin cancer: Verisante AuraTM Near Infrared Raman Pathology on Spectroscopy every lesion scanned Differentiates between malignant and benign tissue Handheld probe scans for 21 biomarkers in an instant Provides data on chemical composition of skin based Rapid speed enables on molecular vibrations full body scans
  • 8. 9Highly automated detection process Skin cancer: Verisante AuraTMSafe, Non-invasive, Fast Increased survival rates Reduced treatment costs No unnecessary biopsies Reduced waiting timesReal time results97% accurate for melanoma91% for other skin cancers
  • 9. 10Proven in clinical trials by the BC Cancer Agency Skin cancer: Verisante AuraTM 6 year clinical study at Vancouver General Hospital’s Skin Care Center Melanoma 97% sensitivity Focused on differentiating cancerous lesions “Percentage identified” from benign lesions 78% specificity “Confirmed by biopsy” 1,000 skin lesions scanned Preliminary results published in 2008 based on Cancerous and Precancerous Lesions 274 lesions 12 91% sensitivity “Percentage identified” 75% specificity “Confirmed by biopsy”
  • 10. 11Superior technology over competing systemsVerisante Aura™ Scibase Inc. • Electrical Impedance Spectroscopy Proven technology • 98% sensitivity; specificity < 5% • Slightly invasive Detects all skin cancers • 5 minutes per lesion • Large probe/expensive disposables 97% Sensitivity; 78% Specificity Mela Sciences for melanoma • Computerized Imaging Technology • FDA Panel recommends approval by narrow margin Measures 21 biomarkers • Key Concern: too many false positives • 98% sensitivity; 9.5% specificity Virtually instant scan • Large probe Lucid Inc. Non-invasive • Confocal Microscopy Tiny Probe • 10-20 min. per lesion • Dermatologist required • Large probe Inexpensive disposable covers
  • 11. 12Endoscopic system enables detection of other cancers Verisante CoreTM Clinical studies underway at VGH for early detection of lung & colon cancerLung Cancer 13World’s #1 cancer killer with1.4 million deaths/yearColon Cancer#2 deadliest cancer in U.S.Cervical CancerWorld’s #2 cause of cancerdeaths among women
  • 12. 13Strong scientific pedigree Focused on developing systems for the early detection of cancerDr. Branko PalcicPh.D.• Honorary Professor, Dept. of Pathology and Laboratory Medicine, UBC• Founder, Cancer Imaging and Technology Departments, BC Cancer Agency• Co-inventor of LIFE-Lung device, used in over 150 major medical centers world-wide• Friesen-Rygiel Award for Outstanding Canadian Academic Discovery (1999)• King George V Silver Jubilee Cancer Research FellowDr. Haishan ZengPh.D.• Senior Scientist, Integrative Oncology Dept. BC Cancer Agency• Associate Professor, Dermatology and Skin Science, University of British Columbia• Co-inventor - Verisante™ technology
  • 13. 14Strong scientific pedigree Focused on developing systems for the early detection of cancerDr. David McLeanMD, FRCPC• Professor, Dept. of Dermatology and Skin Science, UBC• President, Cancer Prevention Institute of Canada• Former President, Canadian Dermatology Association• Co-inventor - Verisante™ technologyDr. Harvey LuiMD, FRCPC• Professor and Head, Dept. of Dermatology and Skin Science, UBC• Former Clinical Fellow, Massachusetts General Hospital, Harvard Medical School• University Killam Prize (2001)• Co-inventor - Verisante™ technology
  • 14. 15Clear regulatory pathway to commercialization Skin cancer: Verisante AuraTM2010 2011 2012 2013 2014 2015 Production Prototype & Health Canada Approval Marketing and Sales (Canada) CE Mark Marketing and Sales (EU, South Africa, Australia) Clinical Study Clinical Study Prep. USA Approval Marketing and Sales (USA)
  • 15. 16Significant market potential with multiple end users Skin cancer: Verisante AuraTM Initial Geographic Markets Staged Rollout Strategy Recurring revenue from sale of disposable probe shields STEP 1 Early adopters ~32,000 Dermatologists Canada EU USA STEP 2 Innovators South ~950,000 General Practitioners Africa STEP 3 Australia Skin Care Clinics NZ Oncology and Imaging Clinics HMOs
  • 16. 17Initial focus on early adopters and innovators Will drive broader market acceptance 2000 Targeting 14% penetration by year 5 1600 Dermatologists United States 1200 Canada, European Union, South Africa, 800 Australia, New Zealand 400 0 Yr. 1 Yr. 2 Yr. 3 Yr. 4 Yr. 5
  • 17. 18Initial focus on early adopters and innovators Will drive broader market acceptance 35000 Targeting 6% 30000 penetration by year 5 General Practitioners 25000 United States 20000 15000 Canada, European Union, South Africa, Australia, New Zealand 10000 5000 0 Yr. 1 Yr. 2 Yr. 3 Yr. 4 Yr. 5
  • 18. 19Experienced management Focus: controlling costs, accelerating product development & regulatory approval processThomas BraunBA, JD, LLM – Chief Executive Officer• Public company experience• Extensive experience in executing M&As and raising capital• Advised high tech companies on international business transactions• Expertise in technology licensing• Member California Bar AssociationAnna TrinhB.Comm, LLB – Chief Financial Officer and Corporate Counsel• Experience in counseling companies on regulatory and compliance filings• M&A and financial transaction experience• Practiced corporate securities law in private practice
  • 19. 20Strong, independent Board of DirectorsJoe Biegel Chris DennisBS, MS (Medical Imaging) MBA• Vice-President, Product Management & Marketing • Former President, Comcare Health Services• McKesson Medical Imaging Group • Senior positions with Angiotech• Senior positions with Agfa Healthcare, Hewlett Pharmaceuticals, Johnson & Johnson / Ortho Packard, Polaroid Medical Imaging NeutrogenaKaren Boodram Jake ThiessenBSc, MBA Ph.D.• Vice-President, Business Development, SemBiosys • Professor Emeritus, University of Toronto• Former Life Sciences Analyst, PI Financial • Founding Director, School of Pharmacy and• More than 25 years healthcare experience Health Sciences Campus, University of Waterloo• Ten years with Novartis
  • 20. 21Share Capital Common Shares 46,188,117 Common Shares (held by Founders) 14,700,000 Total Common Shares Outstanding 60,888,117 Warrants 17,568,600 Incentive Stock Options 3,545,000 Fully Diluted Share Capital 82,001,717
  • 21. 22Market Comparables Company Market Capitalization MELA Sciences, Inc. (NASDAQ: MELA) $93,000,000 Novadaq (TSX: NDQ) $126,000,000 ALI Technologies Inc. $530,000,000 *Sold to McKesson (NYSE: MCK) in 2002 for $530 Million
  • 22. 23Summary Breakthrough early stage skin cancer detection device Patented technology with exclusive worldwide license from BC Cancer Agency Clear regulatory pathway to commercialization with significant market potential Endoscopic device for early stage detection of lung, colon and cervical cancers in clinical trials Strong scientific pedigree and experienced management
  • 23. 24End Notes References1. American Cancer Society. Cancer Facts & Figures 20092. National Cancer Institute. Cancer Trends Progress Report 2007, Update April 20083. American Cancer Society. Cancer Facts and Figures 20094. Melanoma Research Foundation5. National Cancer Institute. SEER Cancer Statistics Review, 1975-20046. National Center for Chronic Disease Prevention and Health Promotion7. Rogers HW, Weinstock MA, et al. Incidence Estimate of Non Melanoma Skin Cancer in the U.S., 2006, Archives of Dermatology 20108. National Cancer Institute. Cancer Trends Progress Report 20079. Doru Traian Alexandrescu. Melanoma Costs: A Dynamic Model Comparing Estimated Overall Costs of Various Clinical Stages, Dermatology Online Journal, Nov 200910. Heal CF, Raasch BA, Buettner PG, Weeden D. Accuracy of Clinical Diagnosis of Skin Lesions, British Journal of Dermatology 200911. Jones TP, Boiko PE, Piepkorn MW. Skin biopsy indications in primary care practice: a population-based study. JABFP 1996; 9:397–404.12. Raman Spectroscopy for In Vivo Tissue Analysis and Diagnosis, Instrument Development to Clinical Applications, Journal of Innovation in Optical Health Sciences 200813. Cancer Research UK14. National Cancer Institute. SEER Database, 1998 – 200015. Melamed MR, Flehinger BJ, Zamen MB, et al. Screening for early lung cancer: results of the Memorial Sloan-Kettering study In New York. Chest 86:44-53, 1984.16. Cortese DA, Pairolero PC, Bergstralh EJ, et al. Roentgenographically occult lung cancer. A ten-year experience. J Thorac Cardiovasc Surg 86:373—80, 1983
  • 24. 25Thank you